Related Experiment Video
Updated: Aug 21, 2025

The Soft Agar Colony Formation Assay
Published on: October 27, 2014
Ivermectin inhibits tumor metastasis by regulating the Wnt/β-catenin/integrin β1/FAK signaling pathway
Lu Jiang1,2, Ying-Jian Sun3, Xiao-Hua Song1
1Laboratory of Molecular Toxicology, Institute of Zoology, State Key Laboratory of Integrated Management of Pest Insects and Rodents, Chinese Academy of Sciences Beijing 100101, China.
Abstract:
Tumor metastasis is the major cause of cancer mortality; therefore, it is imperative to discover effective therapeutic drugs for anti-metastasis therapy. In the current study, we investigated whether ivermectin (IVM), an FDA-approved antiparasitic drug, could prevent cancer metastasis. Colorectal and breast cancer cell lines and a cancer cell-derived xenograft tumor metastasis model were used to investigate the anti-metastasis effect of IVM. Our results showed that IVM significantly inhibited the motility of cancer cells in vitro and tumor metastasis in vivo. Mechanistically, IVM suppressed the expressions of the migration-related proteins via inhibiting the activation of Wnt/β-catenin/integrin β1/FAK and the downstream signaling cascades. Our findings indicated that IVM was capable of suppressing tumor metastasis, which provided the rationale on exploring the potential clinical application of IVM in the prevention and treatment of cancer metastasis.
Insights
Ivermectin (IVM), an antiparasitic drug, effectively inhibits cancer cell migration and metastasis in preclinical models. This study supports exploring IVM for anti-metastasis cancer therapy.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Tumor metastasis is a primary driver of cancer-related mortality.
- Effective anti-metastasis therapies are crucial for improving patient outcomes.
- Ivermectin (IVM), an FDA-approved antiparasitic, is explored for novel therapeutic applications.
Purpose of the Study:
- To investigate the potential of ivermectin (IVM) as an anti-metastasis agent.
- To evaluate the efficacy of IVM in inhibiting cancer cell motility and tumor metastasis.
- To elucidate the molecular mechanisms underlying IVM's anti-metastatic effects.
Main Methods:
- Utilized colorectal and breast cancer cell lines for in vitro studies.
- Employed a xenograft tumor metastasis model for in vivo evaluation.
- Analyzed the expression of migration-related proteins and signaling pathways.
Main Results:
- Ivermectin significantly inhibited cancer cell motility in vitro.
- IVM demonstrated significant suppression of tumor metastasis in vivo.
- Mechanistically, IVM suppressed Wnt/β-catenin/integrin β1/FAK signaling pathways.
Conclusions:
- Ivermectin exhibits potent anti-metastatic properties in preclinical cancer models.
- IVM's mechanism involves the inhibition of key migration-related signaling cascades.
- These findings provide a strong rationale for investigating IVM in clinical settings for cancer metastasis prevention and treatment.
Related Concept Videos
Canonical Wnt Signaling Pathway
Non-Canonical Wnt Signaling Pathways
Mitogens and the Cell Cycle
Inhibition of Cdk Activity
Drugs that Stabilize Microtubules
Intracellular Signaling Affects Focal Adhesions
Some...

